Clinical Trial Update: Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating switching from current cART to Triumeq with adherence support for HIV control in vulnerable populations completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: HIV Infections | Phase 4 | Status: COMPLETED